期刊
DIABETES TECHNOLOGY & THERAPEUTICS
卷 23, 期 -, 页码 S45-S55出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/dia.2021.0193
关键词
Continuous Glucose Monitoring; Eligibility criteria; Type 2 diabetes; Blood glucose monitoring
资金
- Abbott Diabetes Care
Recent studies have shown the clinical utility of CGM in T2D patients, with significant reductions in A1c levels and health resource utilization. However, current eligibility criteria are denying many individuals access to this valuable technology. Therefore, modifying these criteria is necessary for more people to benefit from CGM.
Recent studies have demonstrated the clinical utility of continuous glucose monitoring (CGM) use in type 2 diabetes (T2D) patients who are treated with intensive insulin management. Large retrospective database analyses of T2D patients treated with less-intensive therapies have also shown that CGM use was associated with significant reductions in hemoglobin A1c levels and health resource utilization, including diabetes-related hospitalizations and emergency room care. Despite the growing body of evidence supporting CGM use in the broader T2D population, current eligibility criteria required by public and many private insurers are denying millions of individuals with T2D access to this valuable technology. In this article, we discuss an evidence-based rationale for modifying current eligibility requirements for CGM coverage.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据